Clinical Trial: Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)

U.S., Dec. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07272889) titled 'Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)' on Nov. 19.

Brief Summary: Drug-drug interaction study between Ethinyl Estradioll/Levonorgestrel and Bemnifosbuvir/Ruzasvir

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Healthy Volunteer Study

Intervention: DRUG: Ethinyl Estradioll/Levonorgestrel (EE/LNG)

Treatment-A (EE/LNG): A single 0.03 mg/ 0.15 mg dose of EE/LNG (1 x 0.03 mg/ 0.15 mg tablet) will be administered in the morning under fasting conditions on Day 1.

DRUG: Bemnifosbuvir/Ruzasvir (BEM/RZR)

Treatment-B (BEM/RZR): A 550 mg/180 mg ...